AU2020283129A1 - Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative - Google Patents

Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative Download PDF

Info

Publication number
AU2020283129A1
AU2020283129A1 AU2020283129A AU2020283129A AU2020283129A1 AU 2020283129 A1 AU2020283129 A1 AU 2020283129A1 AU 2020283129 A AU2020283129 A AU 2020283129A AU 2020283129 A AU2020283129 A AU 2020283129A AU 2020283129 A1 AU2020283129 A1 AU 2020283129A1
Authority
AU
Australia
Prior art keywords
crystalline polymorph
provides
cancer
xrpd pattern
degrees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020283129A
Other languages
English (en)
Inventor
Alan Cooper
Shanming KUANG
Zheqiong WU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bantam Pharmaceutical LLC
Original Assignee
Bantam Pharmaceutical LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bantam Pharmaceutical LLC filed Critical Bantam Pharmaceutical LLC
Publication of AU2020283129A1 publication Critical patent/AU2020283129A1/en
Priority to AU2026201586A priority Critical patent/AU2026201586A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2020283129A 2019-05-31 2020-05-29 Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative Abandoned AU2020283129A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026201586A AU2026201586A1 (en) 2019-05-31 2026-03-03 Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962855671P 2019-05-31 2019-05-31
US62/855,671 2019-05-31
PCT/US2020/035343 WO2020243584A1 (en) 2019-05-31 2020-05-29 Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026201586A Division AU2026201586A1 (en) 2019-05-31 2026-03-03 Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative

Publications (1)

Publication Number Publication Date
AU2020283129A1 true AU2020283129A1 (en) 2022-02-03

Family

ID=71787116

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020283129A Abandoned AU2020283129A1 (en) 2019-05-31 2020-05-29 Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative
AU2026201586A Pending AU2026201586A1 (en) 2019-05-31 2026-03-03 Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026201586A Pending AU2026201586A1 (en) 2019-05-31 2026-03-03 Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative

Country Status (7)

Country Link
US (1) US12378234B2 (https=)
EP (1) EP3976606A1 (https=)
JP (2) JP2022534429A (https=)
CN (1) CN114901655A (https=)
AU (2) AU2020283129A1 (https=)
CA (1) CA3142196A1 (https=)
WO (1) WO2020243584A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3081983A1 (en) * 2016-11-30 2018-06-07 Bantam Pharmaceutical, Llc Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US12150934B2 (en) 2016-11-30 2024-11-26 Bantam Pharmaceutical, Llc Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases
CA3081983A1 (en) * 2016-11-30 2018-06-07 Bantam Pharmaceutical, Llc Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases

Also Published As

Publication number Publication date
CA3142196A1 (en) 2020-12-03
AU2026201586A1 (en) 2026-03-19
JP2022534429A (ja) 2022-07-29
CN114901655A (zh) 2022-08-12
US20220162204A1 (en) 2022-05-26
WO2020243584A1 (en) 2020-12-03
US12378234B2 (en) 2025-08-05
EP3976606A1 (en) 2022-04-06
JP2025160244A (ja) 2025-10-22

Similar Documents

Publication Publication Date Title
JP5323289B1 (ja) 新規ピペリジン化合物又はその塩
WO2021057867A1 (zh) 一类基于有机胂的cdk抑制剂及其制备方法和用途
JPWO2020045334A1 (ja) 光学活性なアザビシクロ環誘導体
JP7853221B2 (ja) ４－アミノ－５－（６－（４－メチルピペラジン－１－イル）－１ｈ－ベンゾ［ｄ］イミダゾール－２－イル）チエノ［２，３－ｂ］ピリジン－６（７ｈ）－オンの塩及び結晶形
SG178351A1 (en) Compounds and compositions as protein kinase inhibitors
KR101738866B1 (ko) 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n'-다이아릴티오우레아 및 n,n'-다이아릴우레아, 이의 제조방법 및 이의 용도
CN106170288A (zh) 药物化合物
TW201236684A (en) Pharmaceutically acceptable salts of (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide, preparation process and pharmaceutical use there of
HUP0500111A2 (hu) Protein kináz inhibitorként alkalmazható indolinonszármazékok
EP2571867A1 (en) Novel pyrimidine derivatives
EP2776407A1 (en) Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto
AU2026201586A1 (en) Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative
JP2020523348A (ja) プロテインキナーゼ阻害剤としてのアミノチアゾール化合物
JP2020536113A (ja) 上皮成長因子受容体阻害剤
US20070244110A1 (en) Treatment of prostate cancer, melanoma or hepatic cancer
EP2897952A1 (en) 4-(indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
JP2019512011A (ja) 置換のアミノ６員窒素含有複素環式化合物およびその製造と使用
WO2023109751A1 (zh) 嘧啶或吡啶类衍生物及其医药用途
CN104045632B (zh) 抗肿瘤药物苯并二氢吡喃（噻喃）酰胺类化合物及其药学上可接受的盐及制备方法和应用
TWI920085B (zh) 4-胺基-5-(6-(4-甲基哌-1-基)-1h-苯并[d]咪唑-2-基)噻吩并[2,3-b]吡啶-6(7h)-酮之鹽及晶形
RU2786524C2 (ru) Ингибиторы рецептора эпидермального фактора роста
WO2014182688A1 (en) Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted